GlassScriptPhysician profile
Kathe S Bryson
NPI 1043206303
$7,461.54
in general payments reported to CMS, 2019-2025
17 companies · $901 in 2025
The $901 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $253 · 2020: $336 · 2021: $430 · 2022: $1,116 · 2023: $2,895 · 2024: $1,530 · 2025: $901.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,228 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,227.74 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $2,859.57 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Abbvie INC. | $1,016.36 | 2021-2025 | Rinvoq, Skyrizi, Humira |
| Amgen INC. | $804.19 | 2019-2024 | Enbrel, Otezla, Tavneos |
| Pfizer INC. | $762.50 | 2019-2025 | |
| Ucb, INC. | $688.74 | 2019-2025 | Cimzia, Bimzelx |
| Novartis Pharmaceuticals Corporation | $430.42 | 2019-2025 | |
| Glaxosmithkline, LLC. | $228.12 | 2019-2025 | Benlysta, Nucala |
| Astrazeneca Pharmaceuticals LP | $188.38 | 2023-2024 | Saphnelo, Evusheld |
| Boehringer Ingelheim Pharmaceuticals, INC. | $132.77 | 2022-2025 | Ofev, Cyltezo |
| Janssen Scientific Affairs, LLC | $128.99 | 2022 | |
| Lilly USA, LLC | $62.61 | 2022-2023 | Taltz |
| Mallinckrodt Hospital Products INC. | $60.52 | 2023-2024 | Acthar |
| E.R. Squibb & Sons, L.L.C. | $25.44 | 2025 | Orencia |
| Regeneron Healthcare Solutions, INC. | $20.48 | 2020 | |
| Sandoz INC. | $18.30 | 2023 | Hyrimoz |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius Kabi USA, LLC | $17.94 | 2024 | Idacio |
| Horizon Therapeutics Plc | $16.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathe Bryson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.